跳至主要内容
临床试验/NCT04878237
NCT04878237已完成不适用

Mapping the Kinetics of Cytokine Responses to Mechanical Stimulation of the Nose in Asthmatic, Allergic and Non-Allergic Subjects - A Pilot Study

Medical University of Vienna1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2021年3月25日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
30
试验地点
1
主要终点
Nasal cytokine responses to repeated mechanical stimulation in allergics, non allergics and asthmatics.

研究概览

简要总结

IgE-associated allergy is a hypersensitivity disease affecting more than 40% of the population in industrialised countries. Recently the kinetics of change of clinical and immunological parameters (e.g. nasal blockage and cytokine profiles) in response to allergen exposure have been described. Additionally through recent placebo controlled studies it has become clear that the response of certain cytokines can not only be triggered by allergen exposure but also mechanically e.g through the insertion of nasal swabs for collection of cytokines. However it is not clear to what extent the mechanically triggered cytokine responses may differ between healthy, allergic and asthmatic patients who have been shown to have different cytokine profiles in their nasal secretions and varying impairment of their respiratory epithelium. As collection devices for nasal secretions are frequently used in clinical studies, the investigators aim to assess the impact of mechanical stimulation by frequent cytokine sampling on the cytokine profile.

详细描述

Allergic rhinitis (AR) and allergic asthma are a common manifestations of Type I allergy, an IgE-mediated hypersensitivity disease estimated to affect as much as 40% of the global population . IgE is produced by B cells and binds to the surface of mast cells and basophils via its high affinity Fce receptor I (FceRI). Crosslinking of surface IgE by its specific allergen induces degranulation of the cells as well as release of inflammatory mediators. This process which develops over minutes leads to the typical ocular, nasal and pulmonary symptoms of AR and asthma such as itching, reddening of the eyes, runny and/or congested nose and wheezing due to air trapping as a result of lower airway obstruction. Some patients may also develop late phase reactions (LPR). These responses typically develop 2-6 hours after allergen exposure, peaking in intensity between 6-9 hours and are mostly characterised by tissue oedema which manifests as airflow obstruction in the airways.

Since the introduction of easy to use and highly absorptive mucosal fluid sampling devices the mediators involved in the immediate and late phase allergic responses and the kinetics of their release have become well characterised over the past few years. Efforts by Imperial College London and unpublished data from the investigators group in Vienna have shown that key mediators involved in the immediate phase include mast cell derived mediators, (Tryptase, PGD2), epithelial alarmins (IL-33, sST2), and complement (C3a, C4a, C5a, D-Dimer). Mediators involved in the late phase reactions also include alarmins (sST2, TSLP), Th2 cytokines (IL-4, IL-5, IL-13), neutrophil mediators (MMP-9) and eosinophil mediators (EDN).

However what has also recently become clear through placebo controlled studies is that some mediators are mechanically mediated (unpublished observations), being released into the extracellular environment as a result of the sampling process itself. This is of vital interest as understanding which cytokines are mechanical and which are allergen specific will help guide future studies attempting to target specific biomarkers for treatment or disease monitoring. In order to understand if the mechanical release plays any role in the pathological response to allergens different patient cohorts will need to be investigated to see if their responses differ in any way.

Rational of the Study

In light of this the investigators propose a study to investigate the effects of mucosal sampling on cytokine release from nasal epithelium. The investigators plan to sample different patient cohorts (allergic rhinitis, allergic asthma, non-allergic) to see how mechanical effects are influenced by sampling and allergic or non-allergic status. By including 10 patients in each group the investigators hope to establish a range of "normal" for mechanical release of allergen relevant cytokines in each study group which will help inform future studies investigating allergen specific responses. In order to map both the symptomatic and objective responses to airway sampling, symptom scores and airway flow meters will be employed. To map the kinetics of responses the participants will undergo a mucosal sampling time course over the course of an 8 hour period on a single day. As no interventional substances are being given, this study will carry very low risk to the individuals involved while shedding important light on the epithelial responses to mechanical manipulation.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
All
接受健康志愿者
是

入选标准

  • •Male or female
  • •18 to 50 years of age
  • •Willingness to comply with the study protocol and written informed consent
  • •Subjects must have a standard health care insurance
  • •Subjects must be available during the study period to complete all treatments and assessments
  • •Allergic Rhinitis
  • •Moderate to severe allergic rhinitis to grass pollen for at least two seasons according to medical history
  • •Skin prick test positive to grass pollen extract
  • •Blood ImmunoCAP sensitisation to grass pollen (>0.35 kU/L grass pollen extract specific IgE or higher as determined by UniCAP-FEIA)
  • •No history of Asthma
  • •Allergic Asthma
  • •Clinical history of asthma
  • •Spirometry reversibility or PC20 methacholine/histamine <8mg
  • •Skin prick test positive to grass extract
  • •Blood ImmunoCAP sensitisation to grass pollen (>0.35 kU/L grass pollen extract specific IgE or higher as determined by UniCAP-FEIA)
  • •Non-Allergics
  • •No history of Asthma
  • •No history of allergy
  • •Negative skin prick test to a common skin prick test panel including grass pollen
  • •No ImmunoCAP sensitisation to to grass pollen (<0.35 kU/L grass pollen extract specific IgE or higher as determined by UniCAP-FEIA)

排除标准

  • •Older than 50 or younger than 18 years
  • •Active smoker
  • •History of anaphylaxis
  • •Any severe chronic, malignant or general disease
  • •Treatment with systemic or topical (intranasal, inhaled, external) corticosteroids within the previous 2 months before the start of the study
  • •Treatment with antihistamines 3 days prior to the screening visit of the study
  • •Treatment with other immunosuppressant drugs within the previous 6 months prior to the start of the study
  • •Arterial hypertension or use of anti-hypertensive therapy, including beta-blockers
  • •Contra-indications to skin prick testing such as: skin inflammation in the test area, urticaria facticia
  • •Pregnant, lactating or sexually active women with childbearing potential who are not using a medically accepted birth control method
  • •A mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study, and/or evidence of an uncooperative attitude
  • •Participation in another clinical trial within one month prior to the study; however participation during the previous month solely in the form of blood donation and/or without other interventions will be accepted
  • •Known alcohol or drug addiction or abuse
  • •Risk of non-compliance with the study procedure
  • •Previous immunotherapy with grass pollen
  • •Nasal polyps, history of chronic sinusitis or substantial deviation of the nasal septum

研究组 & 干预措施

Non Allergic Patients

Placebo Comparator

干预措施: Nasal Secretion Sampling (Other)

Allergic Asthma Patients

Active Comparator

Allergy to Grass Pollen

干预措施: Nasal Secretion Sampling (Other)

Allergic Rhinitis Patients

Active Comparator

Allergy to Grass Pollen

干预措施: Nasal Secretion Sampling (Other)

结局指标

主要结局

Nasal cytokine responses to repeated mechanical stimulation in allergics, non allergics and asthmatics.

时间窗: 1 Year

The change in concentrations over time of a panel of relevant cytokines in Th2 immune responses e.g. IL-4, 5, 13 (all in pg/ml) will be measured using MSD multiplex assays to map responses to mechanical stimulation of the nasal mucosa.

次要结局

  • Changes in nasal airflow as a result of repeated nasal sampling(1 Year)
  • Changes in nasal symptoms using the a validated nasal symptom scoring system(1 Year)
  • Defining differences in baseline and post sampling cytokine nasal mRNA levels(1 Year)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Sven Schneider, MD

Principal Investigator

Medical University of Vienna

研究点 (1)

Loading locations...

相似试验